Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

被引:8
|
作者
Axilrod, Andrew C. [1 ]
机构
[1] Hosp Univ Penn, Div Urol, Philadelphia, PA 19104 USA
关键词
Comorbidities; erectile dysfunction; erection; first-dose success; PDE5; inhibitors; vardenafil;
D O I
10.1185/030079907X242656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Erectile dysfunction (ED) is increasingly being recognized as a sentinel marker of future subsequent cardiovascular disease (CVD). Predicted increases in the prevalence of ED are due to a combination of an aging population and the increasing presence of comorbid conditions (hypertension, dyslipidemia, and diabetes). The dichotomy of the situation is that ED is often associated with these comorbidities, potentially leading to greater CVD risk, and conversely, these comorbidities have also been shown to increase the risk of developing ED. The successful treatment of ED with phosphodiesterase type 5 (PDE5) inhibitor therapy, therefore, is of paramount importance because it not only plays a critical role in restoring erectile function, but also provides clinicians with the opportunity to mitigate existing cardiovascular comorbidities or prevent the occurrence of CVD in this patient population. Methods:This review is based on an electronic literature search of databases, including MEDLINE/PubMed, with information selected for its relevance to PDE5 inhibitor therapy comprising efficacy (e.g., first-dose success) in men with ED with or without comorbidities, onset and duration of action at specific time points, and patient preference. Results: The introduction of PDE5 inhibitors represented a major advance in the treatment of ED. In spite of the availability of these agents, a large percentage of men are still not being treated, in many cases because of their reluctance to seek medical help. Moreover, many men who start treatment with PDE5 inhibitors discontinue treatment. Reasons for discontinuation are many and complex, including lack of initial or first-time success. Although of major concern to both patients and clinicians, there remains limited published clinical data on this specific parameter in the pertinent patient population and from prospective, randomized clinical studies. Conclusion: Data from studies suggests that the available PDE5 inhibitor therapies are effective in treating men with ED, including those who have increased CVD risk and those who have clinically identified cardiovascular comorbidities such as hypertension, dyslipidemia, and/or diabetes. According to data from studies, the attributes of PDE5 inhibitor therapy that matter more to clinicians and patients and that hold influence over treatment compliance include effectiveness in patients with cardiovascular comorbidities, first dose effectiveness or early success, rapid onset of action, reliability, and tolerability.
引用
收藏
页码:3189 / 3198
页数:10
相关论文
共 50 条
  • [21] Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus
    Vickers, MA
    Satyanarayana, R
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2002, 14 (06) : 466 - 471
  • [22] Alvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin
    Kondoh, Nobuyuki
    Higuchi, Yoshihide
    Maruyama, Takuo
    Nojima, Michio
    Yamamoto, Shingo
    Shima, Hiroki
    JOURNAL OF ANDROLOGY, 2007, : 81 - 81
  • [23] Efficacy and Safety of Mirodenafil, A New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction
    Paick, Jae-Seung
    Ahn, Tai Y.
    Choi, Hyung K.
    Chung, Woo-Sik
    Kim, Je J.
    Kim, Sae C.
    Kim, Sae W.
    Lee, Sung W.
    Min, Kweon S.
    Moon, Ki H.
    Park, Jong K.
    Park, Kwangsung
    Park, Nam C.
    Suh, Jun-Kyu
    Yang, Dae Y.
    Jung, Hyung-Gi
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 (11): : 2672 - 2680
  • [24] Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: Research and clinical implications in erectile dysfunction
    Moreland, RB
    Goldstein, I
    Kim, NN
    Traish, A
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1999, 10 (03): : 97 - 104
  • [25] The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors
    Cayetano-Alcaraz, Axel Alberto
    Tharakan, Tharu
    Chen, Runzhi
    Sofikitis, Nikolaos
    Minhas, Suks
    ANDROLOGY, 2023, 11 (02) : 257 - 269
  • [26] PERCEPTIONS OF ERECTILE DYSFUNCTION THERAPY AND ACCEPTANCE OF AN ORODISPERSIBLE PHOSPHODIESTERASE TYPE 5 DRUG FORMULATION AMONG PATIENTS AND PHYSICIANS
    Perelman, M.
    Edwards, D.
    JOURNAL OF MENS HEALTH, 2010, 7 (03) : 325 - 325
  • [27] Phosphodiesterase type 5 inhibitor treatment of erectile dysfunction may impart long-term benefits for patients with depression
    Nurnberg, HG
    Siegel, R
    JOURNAL OF ANDROLOGY, 2005, : 73 - 73
  • [28] Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy
    Kim, Su Jin
    Kim, Ju Ho
    Chang, Hyun-Kyung
    Kim, Khae Hawn
    JOURNAL OF EXERCISE REHABILITATION, 2016, 12 (03) : 143 - 147
  • [29] Patients responding to phosphodiesterase type 5 inhibitor therapy - What do their sexual partners know?
    Klotz, Theodor
    Mathers, Mike
    Klotz, Rosemarie
    Sommer, Frank
    JOURNAL OF SEXUAL MEDICINE, 2007, 4 (01): : 162 - 165
  • [30] Drug combinations in the therapy of low response to Phosphodiesterase 5 inhibitors in patients with erectile dysfunction
    Dunzendorfer, U
    Behm, A
    Dunzendorfer, E
    Dunzendorfer, A
    IN VIVO, 2002, 16 (05): : 345 - 348